Skip to main content
US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
RN

RNLXYStockRenalytix plc

Healthcare · GB

$3.70 last close 2026-11-06
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment RNLXY's does — no target price to set, unlike a price alert.

Sharia status
NOT YET SCREENED
Not screened yet — no methodology has been established for this symbol
HTR non-permissible income <0.01%

Methodology breakdown computing — it will appear here on its own.

🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
No active setup right now. The technical picture doesn't show a clear edge — check back when the trend or momentum shifts.

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure2 of 3 timeframes bullish · 84.6% aligned
VWAPPrice below VWAP ($3.75)
VolumeRelative volume 0.5× the 20-day average
Momentum10-day rate of change +4.1%
Market & analysts
Wall Street consensus
BUY
5 analysts
Price target
$0.28
-92.4% · 1 analysts
Institutional own.
0.0%
of shares
Momentum (10d)
+4.1%
rate of change
SMC grade
C · 55
84.6% aligned
100.00% *
Purification ratio (secondary provider, uncertain)
<0.01%
Non-permissible income — HTR, from filings (2024-09-30)
C · 55
SMC grade — 84.6% timeframe alignment
+4.1%
Rate of change (10d)
BUY
Wall Street consensus (5)
$0.28
Price target (-92.4%) · 1 analysts
0.0%
Institutional ownership

🕌 In-house Compliance Research

Computing the full ratio and business-activity breakdown for RNLXY — this runs off the critical path so the page paints first. It will appear here on its own.

138.75104.3469.9335.511.102025-11-102026-05-122026-11-06

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance

Not enough completed daily bars to compute pivots.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
3.45 – 4.55
±13.72% from 4.00, made 2026-09-25 · resolves 2026-10-02
BUY
from 19 indicators
61.9% of our last 5789 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 49.9% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

SELL
19 indicators
OscillatorsSTRONG SELL
1 buy · 4 neutral · 2 sell
Moving averagesSELL
5 buy · 0 neutral · 7 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)50.40NEUTRAL
Stochastic %K (14)40.86NEUTRAL
CCI (20)58.37NEUTRAL
Williams %R (14)-59.14NEUTRAL
MACD (12,26,9)0.01BUY
ROC (10)-3.90SELL
Momentum (10)-0.15SELL
EMA (10)3.71SELL
SMA (10)3.72SELL
EMA (20)3.70SELL
SMA (20)3.65BUY
EMA (30)3.68BUY
SMA (30)3.70SELL
EMA (50)3.56BUY
SMA (50)3.80SELL
EMA (100)4.54SELL
SMA (100)2.95BUY
EMA (200)11.37SELL
SMA (200)2.46BUY

About Renalytix plc

Healthcare · Health Information Services

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The company's products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. It has a license agreement with Mount Sinai Health System to develop and commercialize its products in connection with the application of artificial intelligence for the diagnosis of kidney disease. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. The company was incorporated in 2018 and is based in London, the United Kingdom.

renalytix.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Grade verdict

Average — needs more confirmation before sizing up

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily BULLISH 33
⏱ 15-Min NEUTRAL 15
⏲ 5-Min BULLISH 45

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

+4.1%
Rate of change (10d)
0.5×
Volume vs its 20-day average

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-03 · Asset managers net 928584 (+5135)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.

Tell us what's working, what's confusing, or what you want to see next — read by a real person, not a form that goes nowhere.